What is Cordella?
Cordella, developed by Endotronix, Inc., is a medical technology company focused on delivering an integrated platform for comprehensive health management innovations. Their flagship solution, the Cordella Heart Failure System, aims to assist patients suffering from advanced heart failure. The system incorporates a cloud-based disease management data system and at-home hemodynamic management, featuring a breakthrough implantable wireless pulmonary artery pressure sensor designed for the early detection of worsening heart failure conditions. This technology positions Cordella at the forefront of remote patient monitoring and proactive cardiac care.
How much funding has Cordella raised?
Cordella has raised a total of $128.7M across 10 funding rounds:
Debt
$1.2M
Private Equity
$1.6M
Debt
$2.2M
Debt
$3M
Series B
$3M
Series C
$32M
Debt
$12M
Series D
$70M
Debt
$2M
Debt (2013): $1.2M, investors not publicly disclosed
Private Equity (2014): $1.6M, investors not publicly disclosed
Debt (2014): $2.2M, investors not publicly disclosed
Debt (2015): $3M, investors not publicly disclosed
Series B (2015): $3M, investors not publicly disclosed
Series C (2016): $32M led by BioVentures Investors, SV Life Sciences, APERTURE Venture Partners, and Lumira Capital
Debt (2017): $12M supported by Silicon Valley Bank
Series D (2019): $70M featuring Bioventures Investors, Life Sciences Partners, Seroba Life Sciences, Skydeck LLC, APERTURE Venture Partners, Lumira Capital, Wanxiang Healthcare Investments, SV Health Investors, and OSF Ventures
Debt (2020): $2M backed by PPP
Key Investors in Cordella
Bioventures Investors
BioVentures MedTech Funds is dedicated to investing in innovative companies that are developing advanced medical technologies aimed at improving healthcare outcomes globally. The firm focuses on emerging and growth-stage MedTech companies, providing capital, guidance, and strategic advice to enhance their value.
Life Sciences Partners
European Biotech Acquisition Corp. intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. European Biotech Acquisition Corp. was incorporated in 2021 and is based in Amsterdam, the Netherlands.
Seroba Life Sciences
Seroba is a European life sciences venture capital firm, focused on investing in winning innovations in biotech and medtech. The team has deep investment and industry experience enabling us to help and support entrepreneurs realise their ambitions whilst creating value for investors.
What's next for Cordella?
The substantial enterprise-level backing and recent strategic investment indicate a strong market confidence in Cordella's innovative approach to heart failure management. This capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and expand market reach for the Cordella Heart Failure System. The company is likely to focus on scaling its operations, forging strategic partnerships within the healthcare ecosystem, and potentially pursuing regulatory approvals to broaden its impact on patient care. Continued investment in their proprietary sensor technology and data analytics platform will be key to solidifying their position in the competitive MedTech landscape.
See full Cordella company page
